CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health

Published On 2025-08-24 10:50 GMT | Update On 2025-08-24 10:50 GMT

New Delhi: In a setback to Syneos Health India Private Limited, the Indian arm of the global contract research organization Syneos Health, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has rejected its Phase III clinical trial proposal for QL2107 Injection.

The company had submitted Phase III clinical study protocol no. QL2107-102, version 1.0 dated 03 March 2025 for review. However, the expert panel raised concerns regarding the study design and absence of efficacy endpoints.

After detailed deliberation, the committee opined that, "the proposed clinical trial is focused completely on Pharmacokinetic (pK) parameters. Moreover, primary objective and secondary objective of phase-III study protocol has not been demonstrated for confirmation of therapeutic benefit and efficacy end point. Hence, the committee didn’t recommend to conduct the clinical trial in India.”

Syneos Health, headquartered in the United States, is a global clinical research organization (CRO) that partners with pharmaceutical and biotechnology companies to design and run clinical trials worldwide.

The committee’s rejection signals that the trial, in its current form, does not meet India’s regulatory expectations for Phase III studies, which require demonstration of therapeutic efficacy beyond pharmacokinetics.

Also Read: CDSCO Panel Approves New Indications for Novo Nordisk's Semaglutide, Mandates PMS Study

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health

Similar News

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

CDSCO Panel Nod To Phase I Clinical Trial of Anticancer Drug Bevacizumab by Jeevan Scientific

Fixed Dose Combination of Metformin-Voglibose Now CDSCO Approved

Insufficient Efficacy, Safety Data: CDSCO Panel Rejects Zydus' Phase III CT Waiver Request for Voclosporin

Braille Labels, QR Code Voice Assistance on Drugs? CDSCO Seeks Stakeholder Comments

AstraZeneca Gets SEC Approval to Conduct Phase IV Trial of Hyperkalemia Drug Sodium Zirconium Cyclosilicate

CDSCO Panel Flags Inadequate Data, Withholds Pilot Study Nod for BPH Pulse Field Ablation Device

CDSCO Criminal Prosecution Against IndiaMART Put on Hold by Delhi HC Till Sept 17